DUBLIN, Ireland, January 18 /PRNewswire-FirstCall/ -- Azur Pharma Limited (“Azur Pharma”) today announced that it has acquired the U.S. rights to Gastrocrom(R) (cromolyn sodium, usp Oral Concentrate) from UCB Pharma, Inc (“UCB”). Gastrocrom(R) is indicated in the management of patients suffering from mastocytosis, a rare disorder characterized by an abnormal accumulation of mast cells in various organ systems. Annual sales of Gastrocrom(R) amount to approximately US$5 million.
“I am pleased to announce our first product acquisition, Gastrocrom(R), a mature and stable prescription product indicated for a rare and often chronic disorder. This acquisition is an important first step as we seek to execute on our mission of creating a U.S. pharmaceutical business focused on developing and marketing products in specialist therapeutic areas.” commented Mr. Seamus Mulligan, Azur Pharma’s Chairman and Chief Executive Officer.
About Azur Pharma
Azur Pharma is a privately held pharmaceutical company dedicated to enhancing patients’ lives by developing and marketing pharmaceutical products in specialist therapeutic areas. Azur Pharma’s strategy is to identify, evaluate, selectively acquire and enhance the value of late stage development and FDA approved pharmaceutical products. (Website: www.azurpharma.com)
About UCB
UCB (www.ucb-group.com) is a global biopharmaceutical leader with headquarters in Brussels, Belgium, specialising in the fields of central nervous system disorders, inflammatory diseases, and oncology. UCB employs over 8,500 people operating in over 40 countries. UCB is listed on Euronext Brussels (UCB / UCBBt.BR / UCB BB).
Azur Pharma
CONTACT: Azur Pharma Media Contact: Mr. Ray Gordon, MRPA KinmanConsultants, Telephone: +353-1-7038619/+353-87-2417373, E-mail:ray@mrpakinman.ie
